Prenatal enzyme replacement therapy for $Apk2^{-/-}$ mice with lethal hypophosphatasia

Akihiro Hasegawa $^{a,b}$, Aki Nakamura-Takahashi $^{c}$, Masataka Kasahara $^{c}$, Nana Saso $^{a}$, Sonoko Narisawa $^{d}$, José Luis Millán $^{d}$, Osamu Samura $^{b}$, Haruhiko Sago $^{e}$, Aikou Okamoto $^{b}$, Akihiro Umezawa $^{a,*}$

$^{a}$ Center for Regenerative Medicine, National Center for Child Health and Development, Tokyo, Japan
$^{b}$ Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
$^{c}$ Department of Pharmacology, Tokyo Dental College, Tokyo, Japan
$^{d}$ Sanford Children's Health Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
$^{e}$ Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan

**Abstract**

Hypophosphatasia (HPP) is a congenital skeletal disease. Impairment of bone mineralization and seizures are due to a deficiency of tissue-nonspecific alkaline phosphatase (TNAP). Enzyme replacement therapy (ERT) is available as a highly successful treatment for pediatric-onset HPP. However, the potential for prenatal ERT has not been fully investigated to date. In this study, we assessed outcomes and maternal safety using a combinational approach with prenatal and postnatal administration of recombinant TNAP in $Apk2^{-/-}$ mice as a model of infantile HPP. For the prenatal ERT, we administered subcutaneous injections of recombinant TNAP to pregnant mice from embryonic day 11.5 sequentially to newborn pups from birth to day 18. For the postnatal ERT, we injected $Apk2^{-/-}$ pups from birth until day 18. Prenatal ERT did not cause any ectopic mineralization in heterozygous maternal mice. Both prenatal and postnatal ERT preserved growth, survival rate and improved bone calcification in $Apk2^{-/-}$ mice. However, the effects of additional prenatal treatment to newborn mice appeared to be minimal, and the difference between prenatal and postnatal ERT was subtle. Further improvement of the prenatal ERT schedule and long-term observation will be required. The present paper sets a standard for such future studies.

© 2021, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**1. Introduction**

Hypophosphatasia (HPP, OMIM #241500) is a rare genetic disease characterized by impairment of systemic bone calcification due to a deficiency of tissue-nonspecific alkaline phosphatase (TNAP). The incidence has been estimated as 1 in 538,000 births in Europe from 2000 to 2009 [1], 1:100,000 in the USA [2] but a bit higher in Japan at 2–3 in 100,000 births [3]. TNAP is one of the critical enzymes for skeletal and dental mineralization. Lack of TNAP causes accumulation of inorganic pyrophosphate (PPI, an inhibitor of mineralization) and depletion of pyridoxal 5’-phosphate (PLP), an active form of vitamin B6 [4–6]. The increase in extracellular PPI leads to rickets/osteomalacia, recurrent fractures, hypoplastic thorax, inadequate mineralization of dentin and enamel, and a lack of acellular cementum. Improper metabolism of vitamin B6 leads to seizures which usually heralds a poor outcome.

HPP is classified into six subtypes based on the time of onset: perinatal severe, prenatal benign, infantile, childhood, adult, and odonto type HPP [7–9]. Symptom of perinatal HPP includes shortening and bowing of fetal tubular bones during the second or third trimester of pregnancy [8,10–12]. Impairment of bone...
mineralization starts in utero and, most infants with perinatal severe HPP die at or soon after birth from respiratory insufficiency accompanied by pulmonary hypoplasia [13]. In addition, deficiency of PLP in the brain induces seizures.

Enzyme replacement therapy (ERT) with recombinant mineral-targeted TNAP (asfotase alfa: ENB-0040, Alexion Pharmaceuticals, Cheshire, CT) is effective in these HPP patients as it improves the shortened and bowed tubular bones, extends life expectancy, prevent seizures [14–18] and can be administered right after birth [13]. Furthermore, recombinant TNAP appears able to cross the placenta in mice as per a disclaimer by the manufacturer [19]. In this study, we investigated outcomes and maternal safety using a combination approach with prenatal and postnatal administration of recombinant TNAP in Akp2−/− mice, a model of infantile HPP.

2. Materials and methods

2.1. Ethical statement

The procedures for performing animal experiments were approved by the Institutional Animal Care and Use Committee of the National Research Institute for Child Health and Development (approval letter number: A2004-004), Japan.

2.2. Experimental design

For maternal analysis, we prepared a prenatal ERT maternal group and a control maternal group. For the prenatal ERT maternal group, we administered subcutaneous injections of recombinant TNAP to the back of the necks of pregnant Akp2−/− heterozygous mice at embryonic day (E) 11.5–14.5. For the control maternal group, Dulbecco’s phosphate buffered saline (DPBS) was injected into Akp2−/− heterozygous mice at the same gestation stages. Embryonic days were calculated as E11.5–14.5 from day of mating.

For analysis of 19-day-old pups, we prepared four groups as follows: Akp2−/− mice, untreated Akp2−/− mice, Akp2−/− mice with prenatal and postnatal ERT (prenatal ERT group), and Akp2−/− mice with postnatal ERT (postnatal ERT group). For the prenatal ERT group, pregnant Akp2−/− mice that had been mated with Akp2+/− males were treated with recombinant TNAP starting from the stage of E11.5–14.5 till E18.5 (SC injection, 8.2 mg/kg/day), and their pups received further enzyme treatment (SC injection, 8.2 mg/kg/day) until day 18. For the postnatal ERT group, the mother Akp2−/− mice were not treated with enzyme but their pups received enzyme treatment (SC injection, 8.2 mg/kg/day) until day 18. Genotypes were determined by analyzing DNA from pups’ toes just after birth. Akp2+/− and Akp2−/− mice with prenatal ERT, Akp2−/− mice with postnatal ERT were sacrificed on day 19, and untreated Akp2−/− mice were sacrificed between days 17–19 for collection of samples.  

Asfotase alfa (recombinant mineral-targeted TNAP) was purchased from Alexion Pharmaceuticals.

2.3. Animals and analysis

2.3.1. Lethal type HPP mouse model

The Akp2−/− mice were created by insertion of the Neo cassette into exon 6 of the mouse TNAP gene (Akp2) through homologous recombination [20]. All of Akp2−/− mice were fed a rodent diet supplemented with 325 ppm pyridoxine/10 kg of feed ( Oriental Yeast Co., Ltd., Tokyo, Japan) to prevent seizures [21]. To identify Akp2−/− homozygotes after birth, we extracted DNA from pup’s toe biopsy and performed genotyping by using PCR with the primers as follows: forward, 5′-AAGTTGGGAACGCTTCTC-3′; and reverse, 5′-TGCTGCTCCACTCAGTGAT-3′.

2.3.2. Serum alkaline phosphatase (ALP) activity

For maternal analysis, blood samples were collected from the tail vein with sniping at days 0 and 3, and the inferior vena cava with a 29-gauge needle after finishing breast feeding was discontinued. Day 0 was defined as the day before initiating subcutaneous injection on E11.5–14.5. Day 3 was defined as E15.5–18.5 before birth. Cessation of breast feeding was defined as more than 4 weeks later after delivery. Maternal mice injected with recombinant TNAP were collected blood samples on the day after cessation of breast feeding (n = 3). Maternal mice injected with DPBS were collected blood samples on the day after cessation of breast feeding (n = 3).

For analysis of 19-day-old pups, blood samples were collected from the inferior vena cava using a 29-gauge needle on day 17–19 after birth. Blood samples of Akp2+/− mice and Akp2−/− mice with prenatal ERT, Akp2+/− mice with postnatal ERT were collected on day 20 after birth, and those of untreated Akp2−/− mice were collected on day 17–19 after birth. We analyzed serum from blood that was centrifuged at 12,000 rpm for 5 min (MX-307, TOMY, Japan). ALP activity was measured by a colorimetric assay. The ALP activity in 1 U was defined as the amount of enzyme needed to catalyze the generation of 1 μmol p-nitrophenol per a minute [22].

2.3.3. Computed tomography (CT) analysis

An in vivo CT was used for analysis of the following parameters: bone length, density of cortical, cancellous and total bone, cortical bone area, thickness of cortical bone and minimum moment of inertia of area (Latheta LCT-200; Hitachi Aloka Medical, Japan). Imaging conditions for femur length were as follows: voxel size, 24 × 48 μm; slice pitch, 96 μm; rotation angle 360°; the number of shooting direction 1592. Tube voltage, 50 kV; tube current, 0.5 mA. Three-dimensional CT pictures of maternal bones were reconstructed with Amira 5 software (Maxnet Co.,Ltd, Tokyo, Japan). Imaging conditions for maternal bone were as follows: voxel size, 120 × 480 μm; slice pitch, 1020 μm; rotation angle 180°; the number of shooting direction 872. Tube voltage, 50 kV; tube current, 0.5 mA.

2.3.4. Histological findings

Neck skin samples of the prenatal ERT mother group were taken on the day after cessation of breast feeding (n = 3). Those of the control mother group were taken on the day after cessation of breast feeding (n = 3). Paraffin sections of neck skin were stained with Carazzi’s hematoxylin solution (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 5 min and 1% eosin solution (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 30 s. Knee joints were fixed in 4% paraformaldehyde, embedded in Super Cryoembedding Medium compound (Leica Microsystems, Wetzlar, Germany) and frozen by using dry ice and hexane without decalcification. Sections (10-μm thickness) were prepared by the Kawamoto film method (Leica Microsystems), air-dried for 20 min, and washed with distilled water [23]. As hematoxylin and eosin (H&E) stain, sections were stained with Carazzi’s hematoxylin solution (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 5 min and 1% eosin solution (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 30 s. As Alcian Blue stain, sections were stained with Alcian Blue solution (pH 2.5) (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 30 min, washed with distilled water, and stained with hematoxylin (Leica Microsystems) stain, sections were stained with Alcian Blue solution (pH 2.5) (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 30 min, washed with distilled water, and stained with Alizarin Red S stain (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 27 min.

2.4. Statistical analysis

Statistical analyses were performed by using Prism 8.01 software (GraphPad, Inc.). Data were expressed as the means ± SEM.
Significant differences (p values) between two groups were calculated by using a Student’s t test. One-way analysis of variance (ANOVA) was used for multiple comparisons among each group. Survival rate was evaluated by the Kaplan–Meier method, and differences in the survival rates were assessed by the log-rank test.
3. Results

3.1. Analysis of the maternal mice injected with recombinant TNAP

We assessed maternal conditions such as dermal site reaction, ectopic bone calcification, and ALP activity in serum (Fig. 1B–J). Macroscopic and microscopic analysis revealed no inflammation at subcutaneous injection sites in all maternal mice (Fig. 1B and C). Serum ALP activity significantly increased in maternal mice treated with prenatal ERT (Fig. 1D–F). We also assessed ectopic skeletal mineralization in the maternal mice using whole body CT. We did not detect any ectopic mineralization in the two-dimensional images or video of the whole-body CT (Fig. 1G, supplementary material). We compared cortical bone area ratios in cranial, thoracic, and abdominal regions. We did not find significant differences in cortical bone area ratios (Fig. 1H–J).

Supplementary video related to this article can be found at https://doi.org/10.1016/j.reth.2021.06.002

3.2. Prenatal and postnatal ERT improves growth and femur length and prolongs survival in Akp2+/− mice

For the prenatal ERT group, we performed subcutaneous daily injections of recombinant TNAP (8.2 mg/kg) to E11.5–14.5 pregnant Akp2+/− mice in the back of the neck. We continued daily subcutaneous injections of recombinant TNAP (8.2 mg/kg) from birth to day 18 to Akp2+/− pups. Genotypes were determined by analyzing DNA from the pups’ fingers just after birth. For the postnatal ERT group, we injected recombinant TNAP (8.2 mg/kg) to Akp2+/− daily after birth until day 18. We then analyzed Akp2+/+ (n = 10), prenatal ERT (n = 10), postnatal ERT (n = 10) groups on day 19 after birth (Fig. 2A). Survival rate of Akp2+/+ mice (n = 10), and untreated Akp2+/− mice (n = 10); prenatal ERT Akp2+/− with TNAP mice (n = 10); postnatal ERT Akp2+/− with TNAP mice (n = 10); prenatal ERT Akp2+/− with TNAP mice (n = 8); postnatal ERT Akp2+/− with TNAP mice (n = 8); postnatal ERT Akp2+/− with TNAP mice (n = 8). Data represent the means ± SE. **P < 0.01. (D) Serum ALP activity on day 19, was analyzed in Akp2+/− mice (n = 10), and prenatal ERT Akp2+/− with TNAP mice (n = 5), postnatal ERT Akp2+/− with TNAP mice (n = 4), untreated Akp2+/− mice (n = 10). Data represent the means ± SE. *P < 0.05, **P < 0.01. (E) Femur Length on day 19, was measured in Akp2+/− mice (n = 15), and untreated Akp2+/− mice (n = 9), prenatal ERT Akp2+/− with TNAP mice (n = 5), postnatal ERT Akp2+/− with TNAP mice (n = 9). Data represent the means ± SE. *P < 0.05, **P < 0.01.

Plasma ALP activity on average was as follows; Akp2+/+ on day 19: 0.3435, prenatal ERT (n = 10), postnatal ERT (n = 10) groups, and the untreated Akp2+/− group (n = 10). Mice in the Akp2+/+ group (100%), prenatal ERT group (90%), and postnatal ERT group (90%) survived until day 19. In contrast, all of the untreated Akp2+/− mice died between day 10–19 with a median survival of 13.5 days (Fig. 2A). The survival of the prenatal and postnatal ERT groups was significantly prolonged, compared to the untreated Akp2+/− mice (p < 0.01). Body weights measured at postnatal day 16 of Akp2+/− mice with prenatal and postnatal ERT were similar to those in Akp2+/+ mice (Fig. 2B) compared to the decreased body weight seen in the untreated Akp2+/− mice (p < 0.01) (Fig. 2C).

Plasma ALP activity on average was as follows; Akp2+/+ on day 19: 0.3435, prenatal ERT on day 19:1.298, postnatal ERT on day 19: 1.473, untreated Akp2+/− group on day 17–19: 0.06785 U/ml (Fig. 2D). Plasma ALP activity was significantly high in the prenatal and postnatal ERT group than that in the untreated group. Femur length was also improved in the prenatal and postnatal ERT groups on day 19 after birth, compared with the untreated Akp2+/− mice on day 17–19 after birth (Fig. 2E).

3.3. Prenatal and postnatal ERT improves bone structure and ALP activity in Akp2+/− mice

We performed a histological analysis of the epiphysis, growth plate, and cortical bone of untreated Akp2+/− group on day17–19, prenatal ERT, and postnatal ERT groups on day 19 (Fig. 3). Untreated Akp2+/− mice showed abnormal proliferation and irregular arrangement of chondrocytes in the femurs, a defective formation of bone ends in the
long axis and inadequate secondary ossification (Fig. 3A and B). Strong ALP activity (as shown in purple) was observed in the trabecular bone and periosteal surface in femurs of Akp2−/− mice, and no ALP activity was detected in the femurs of untreated Akp2−/− mice (Fig. 3C). In contrast, ALP activity was present in the growth plate and periosteal periphery of Akp2−/− mice with prenatal and postnatal ERT (Fig. 3C). These results suggest that prenatal and postnatal ERT are both effective treatment options in Akp2−/− mice.

3.4. Skeletal morphological analysis by computed tomography

The trabecular bone region of the femur was analyzed by computed tomography (CT) for evaluation of the bone in each group. CT revealed irregular margin of cortical bone, abnormalities in the structure of the growth plate, and low density of cancellous bone in the untreated Akp2−/− mice (Fig. 4B). Prenatal and postnatal ERT significantly improved cortical bone density in Akp2−/− mice (Fig. 4C). However, prenatal and postnatal ERT failed to improve cancellous bone density, total bone density, cortical bone area ratio and cortical bone thickness (Fig. 4D–G). Prenatal ERT significantly improved the minimal moment of inertia of area while postnatal ERT was less significantly effective (Fig. 4H).

4. Discussion

ERT is currently the first choice of treatment for pediatric onset HPP. In this study, we assessed the potential efficacy of prenatal ERT using the well-established Akp2−/− mouse model of infantile HPP. Presumably, starting ERT as early as possible during fetal life would enhance disease prevention for the fetus. Our data indicate that prenatal administration of ERT significantly prevented bone disease, indicating that an early approach to treatment with mineral-targeted TNAP leads better outcomes. Improvements in bone structure, growth and survival observed in our current postnatal ERT are comparable to those of an earlier report with ERT [14]. These improvements were achieved with an approximately 4-fold increase in plasma ALP activity by ERT in the current study. By contrast, ALP activity can be augmented to more than 20-folds using viral vectors for delivery [24–26]. A recent report using higher doses of a viral vector for delivery of mineral-targeted TNAP leading to a 25-fold increase in serum ALP showed evidence of ectopic calcification [24]. However, under the current experimental conditions prenatal ERT did not show any evidence of ectopic calcification. Improvement of bone structure in the both the prenatal and postnatal ERT groups in this study observed by CT analysis is comparable to the results previously reported using viral vectors.
for delivery [24,26,27]. Improvement of minimum moment of inertia of area with prenatal ERT suggests that reversal of impairment of bone mineralization that is already manifested in fetal life. Indeed, patients with perinatal HPP indeed show symptoms such as shortening and bowing of fetal tubular bones during second or third trimester of pregnancy [8,10–12]. Impairment of bone mineralization starts in utero and, most infants with perinatal HPP die at or soon after birth from respiratory insufficiency following by pulmonary hypoplasia. In addition, deficiency of PLP in the brain induces seizures that usually herald a poor clinical outcome [28] due to improper gabanergic [29] and purinergic signaling [30] in the central nervous system. An early approach using prenatal ERT with recombinant TNAP may thus lead to earlier alleviation of these seizures. In addition, the craniosynostosis manifested in severely

Fig. 4. Comparison of prenatal and postnatal ERT effect by computed tomography analysis. Akp2+/+ mice (n = 15), untreated Akp2+/– mice (n = 9), prenatal ERT Akp2+/– with TNAP mice (n = 5), and postnatal ERT Akp2+/– with TNAP mice (n = 9) were analyzed. Data represent the means ± SE. *P < 0.05, **P < 0.01. ns: not significant. (A) Images of regions of interest (ROIs) in cancellous bone analysis. (B) Two-dimensional images of growth plate and cortical bone of femurs. Scale bars, 750 μm. (C) Cortical bone density. (D) Cancellous bone density. (E) Total bone density. (F) Cortical bone area ratio. (G) Cortical bone thickness. (H) Minimum Moment of inertia of area.
affected subjects and this condition usually requires multiple surgeries throughout life. In HPP mice, craniosynostosis develops approximately 2 weeks after birth [31] and postnatal ERT with both mineral-targeted [32] and non-targeted ERT [33] prevented craniosynostosis in the Alp−/− mouse model of HPP. However, in human perinatal HPP, caput membranaceum, wide suture and fontanelles occur rather than the premature fusion of skull bones [12]. Vulnerability develops in utero, and the ultrasonographic findings of soft calvarium is used differentiates diagnosis from any other congenital skeletal dysplasia. The mechanism of progression from caput membranaceum to craniosynostosis is still not clear. However, prenatal ERT may provide a therapeutic avenue to prevent this significant complication of severe HPP disease.

A primary concern of prenatal ERT is maternal safety. The most common side effects of recombinant TNAP are reaction of the injection site with erythema, pruritus, nodule, and pain [18,34,35]. Ectopic calcification, headache, myalgia, irritability, slight fever, hypocalcemia and hyperphosphatemia are also potential side effects. In our experimental settings, prenatal ERT did not show any negative events such as injection site reaction, ectopic skeletal mineralization and inflammation in the maternal mice. Both prenatal and postnatal ERT improved growth, survival rate and bone calcification in Alp−/− mice. However, the effects of additional prenatal treatment to newborn mice appeared to be minimal, and the difference between prenatal and postnatal ERT was subtle. Further improvement of the prenatal ERT schedule and long-term observation will be required. The present paper sets a standard for such future studies.

Author contribution

AH and AU designed experiments. AH and NS performed experiments. SN and JLM provided materials. AH, NS and AU analyzed data. AH, AT, MK, OS, HS, AO and AU discussed the data and manuscript. AH and SN, JLM contributed to the writing of the manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

All authors declare no conflicts of interest or sources of funding.

Acknowledgement

This work was supported in part by a grant from Japan Society for the Promotion of Science KAKENHI (Grant Number 19K17385) and the Jikei University Research Fund for Graduate Students.

References

